Brief: Newamsterdam Pharma Company NV Issuance Of Composition Of Matter Patent For Obicetrapib By United States Patent And Trademark Office
11/06/2024 13:15
June 11 (Reuters) - NewAmsterdam Pharma Company NV
KH6.F :
* NEWAMSTERDAM PHARMA COMPANY NV: ISSUANCE OF COMPOSITION OF
MATTER PATENT FOR OBICETRAPIB BY UNITED STATES PATENT AND
TRADEMARK OFFICE
* NEWAMSTERDAM PHARMA COMPANY NV: PATENT EXTENDS
OBICETRAPIB'S IP
PROTECTION AND EXCLUSIVITY UNTIL JULY 2043
Source text for Eikon: ID:n0001193125-24-158751
Further company coverage: KH6.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NewAmsterdam Pharma
See all newsBrief: Menarini Group & Newamsterdam Pharma Receive European Commission Approval For Ubeslo And Evlarco
Amgen falls after Novartis trial setback, BMO downgrade
Brief: Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Newamsterdam Pharma Company N.V. - Announces Positive CHMP Opinion For Obicetrapib And Obicetrapib/Ezetimibe
Brief: NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)